HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Keith S. Naunheim Han Kim Arthur E. Baue Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naunheim, K. S. Articles by Baue, A. E. Search for Related Content PubMed PubMed Citation Articles by Naunheim, K. S. Articles by Baue, A. E.

Ann Thorac Surg 1995;59:1085-1091
© 1995 The Society of Thoracic Surgeons

---

Articles

Multimodality therapy for adenocarcinoma of the esophagus

Division of Cardiothoracic Surgery, St. Louis University Health Sciences Center, St. Louis, Missouri, USA

^* Address reprint requests to Dr Naunheim, Department of Surgery, St. Louis University Health Sciences Center, 3635 Vista Ave at Grand Blvd, St. Louis, MO 63110-0250.

Few reports exist detailing results of multimodality treatment for adenocarcinoma of the esophagus. We have treated 28 such patients using a preoperative regimen consisting of two courses of cisplatin and 5-fluorouracil with radiation (either 3,000 or 3,600 cGy). There were 25 men and 3 women (mean age, 62.9 years; range, 35 to 86 years), and 16 patients were known to have Barrett's esophagus. Dysphagia was present for a mean of 2.7 months, and the average weight loss was 6.5 kg. Tumors ranged from 2 to 10 cm in length (mean, 5.2 ± 1.8 cm) with American Joint Committee on Cancer clinical stage I in 2 patients, stage II in 19 patients, and stage III in 7. Dysphagia improved in 23 patients (82%), and in 8 (29%) no tumor was detected during radiologic and endoscopic staging after neoadjuvant therapy. Four patients refused operation. Esophagectomy via standard Ivor Lewis approach was accomplished in 20 of 24 patients (87%) undergoing operation. There were no operative deaths, and mean hospital stay was 15.5 ± 11.6 days. Four patients (17%) were complete responders with no tumor in the resected specimen. Actuarial survival in the 28 patients at 1, 2, and 3 years is 71%, 28%, and 20% respectively. Of the 20 esophagectomy patients, 6 are alive with no evidence of disease at 10, 50, 54, 70, 77, and 84 months. Three of these were complete responders. Only 1 of the 8 patients not undergoing resection is alive at 16 months with no evidence of disease after further radiotherapy and chemotherapy. These data suggest that preoperative combined modality therapy for adenocarcinoma of the esophagus is safe and effective treatment. It results in excellent symptomatic improvement, a complete response rate of 17%, and a significant chance for long-term survival.

This article has been cited by other articles:

				J. L. Port, P. C. Lee, R. J. Korst, Y. Liss, D. Meherally, P. Christos, M. Mazumdar, and N. K. Altorki Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 393 - 400. [Abstract] [Full Text] [PDF]

				J. G. Izzo, A. M. Correa, T.-T. Wu, U. Malhotra, C. K.S. Chao, R. Luthra, J. Ensor, A. Dekovich, Z. Liao, W. N. Hittelman, et al. Pretherapy nuclear factor-{kappa}B status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol. Cancer Ther., November 1, 2006; 5(11): 2844 - 2850. [Abstract] [Full Text] [PDF]

				R. J. Korst, A. L. Kansler, J. L. Port, P. C. Lee, Y. Kerem, and N. K. Altorki Downstaging of T or N Predicts Long-Term Survival After Preoperative Chemotherapy and Radical Resection for Esophageal Carcinoma Ann. Thorac. Surg., August 1, 2006; 82(2): 480 - 485. [Abstract] [Full Text] [PDF]

				B. Agarwal, S. G. Swisher, J. Ajani, K. Kelly, R. R. Komaki, E. Abu-Hamda, A. M. Correa, and J. A. Roth Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux Ann. Thorac. Surg., May 1, 2005; 79(5): 1716 - 1723. [Abstract] [Full Text] [PDF]

				J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus Ann. Thorac. Surg., April 1, 2004; 77(4): 1193 - 1199. [Abstract] [Full Text] [PDF]

				B Dunne, J V Reynolds, E Mulligan, A Kelly, and M Griffin A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy J. Clin. Pathol., November 1, 2001; 54(11): 841 - 845. [Abstract] [Full Text] [PDF]

				M. M. DeCamp Jr, S. J. Swanson, and M. T. Jaklitsch Esophagectomy After Induction Chemoradiation* Chest, December 1, 1999; 116(2011): 466S - 469S. [Abstract] [Full Text] [PDF]

				S. J. Hoff, J. L. Sawyers, C. D. Blanke, H. Choy, and J. R. Stewart Prognosis of Adenocarcinoma Arising in Barrett's Esophagus Ann. Thorac. Surg., January 1, 1998; 65(1): 176 - 181. [Abstract] [Full Text] [PDF]

				J.R. Siewert, H.J. Stein, and U. Fink Multimodality Therapy for Esophageal Cancer Oncologist, August 1, 1996; 1(4): 210 - 218. [Abstract] [Full Text] [PDF]